CoChat

Systemic antifungal therapy in critically ill patients without invasive fungal infection*

Azoulay, Elie, Dupont, Hervé, Tabah, Alexis, Lortholary, Olivier, Stahl, Jean-Paul, Francais, Adrien, Martin, Claude, Guidet, Bertand, Timsit, Jean-François · 2012 · Critical Care Medicine
Cited by 138

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To determine the number of adult or pediatric intensive care unit patients without documented invasive fungal infection who receive systemic antifungal therapy. DESIGN: A 1-day cross-sectional cohort study. SETTING: One hundred sixty-nine intensive care units in France and Belgium. PATIENTS: All patients staying in the participating intensive care units. INTERVENTION: None. MEASUREMENT AND MAIN RESULTS: A hierarchical mixed model was used to identify center-based and patient-based determinants of systemic antifungal therapy use. Day 28 mortality was compared in patients with and without systemic antifungal therapy. Two thousand forty-seven patients were recruited. Systemic antifungal therapy was used in 154 (7.5%) patients, including 100 without and 54 with a proven invasive fungal infection. Overall, systemic antifungal therapy consisted of monotherapy of fluconazole (60%), caspofungin (24%), voriconazole (8%), or liposomal amphotericin B (5%). Independent predictors of systemic antifungal therapy included patient-related factors (severity, emergency surgery, malignancy, Candida colonization, and severe sepsis) and center-related factors (hospital with <800 beds, solid organ transplantation activity, higher annual incidence of candidemia, uncontrolled use of fluoroquinolones, and routine systemic antifungal therapy in patients with unresolved documented or undocumented sepsis). The group given systemic antifungal therapy had greater disease severity and higher rates of sepsis and organ failures. Nevertheless, crude 28-day mortality in the systemic antifungal therapy group was not significantly higher than in the group not given systemic antifungal therapy (20% vs. 19.2%; hazard ratio, 0.97 [0.61-1.52]; p = .88). CONCLUSIONS: Systemic antifungal therapy was used in 7.5% of intensive care unit patients. Two-thirds of patients given systemic antifungal therapy had no documented invasive fungal infection. Our results warrant a trial of systemic antifungal therapy in severely ill intensive care unit septic patients without documented invasive fungal infection based on their severity of illness and the presence of Candida colonization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/ccm.0b013e318236f297

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 138

Metadata

Authors
Azoulay, E., Dupont, H., Tabah, A., Lortholary, O., Stahl, J.-P., Francais, A., Martin, C., Guidet, B., & Timsit, J.-F.
Venue
Critical Care Medicine
Published
2012-03
Volume
40
Issue
3
Pages
813-822
ISSN
0090-3493 (ISSN-L)
OpenAlex
W2322839310
Cited by
138
References
14
FWCI
8.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic antifungal therapy in critically ill patients without invasive fungal infection*. https://app.cochat.ai/papers/10.1097/ccm.0b013e318236f297
The paper
Azoulay, E., Dupont, H., Tabah, A., Lortholary, O., Stahl, J.-P., Francais, A., Martin, C., Guidet, B., & Timsit, J.-F. (2012). Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e318236f297

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.